BJ Bormann is a professional with nearly 30 years of experience in academic and pharmaceutical science and biotechnology and pharmaceutical business development. She most recently served as the Vice President of Translational Science and Network Alliances for the Jackson Laboratory. In this role, Dr. Bormann worked to bring the innovations from the Jackson Laboratory faculty closer to patients by generating a series of collaborative relationships with industrial partners. Dr. Bormann’s previous work in the biotechnology area includes serving as CEO of Pivot Pharmaceuticals (OTC: PVOTF) as well as CEO of Supportive Therapeutics, LLC, a company developing a drug for the treatment of oral mucositis, a severe side effect to chemoradiation treatment in oncology patients.
Dr. Bormann has previously served as the CEO of Harbour Antibodies, based in the Netherlands, licensing transgenic mice that make human antibodies, as well as the Chief Business Advisor for NanoMedical Systems, Inc. of Austin, Texas, which licenses a unique implantable drug delivery device. Prior to these engagements, from 2007–2013, Dr. Bormann was Senior Vice President at Boehringer Ingelheim Pharmaceuticals, Inc., responsible for worldwide alliances, licensing, and business development. From 1996– 2007, she served in a number of positions at Pfizer, Inc., the last one being Vice President of Pfizer Global Research and Development and the worldwide Head of Strategic Alliances.
Dr. Bormann currently serves on the board of directors of various companies, including Supportive Therapeutics, LLC, the Institute for Pediatric Innovation, and Bioline RX (Nasdaq: BLRX). Dr. Bormann received her PhD in Biomedical Sciences from the University of Connecticut Health Center and her BS in Biology from Fairfield University. Dr. Bormann completed postdoctoral training at the Yale School of Medicine in the department of Pathology.
What is Barbara-Jean A. Bormann-Kennedy's net worth?
The estimated net worth of Barbara-Jean A. Bormann-Kennedy is at least $1.09 million as of June 4th, 2026. Bormann-Kennedy owns 126,500 shares of Xeris Biopharma stock worth more than $1,090,430 as of July 10th. This net worth evaluation does not reflect any other assets that Bormann-Kennedy may own. Learn More about Barbara-Jean A. Bormann-Kennedy's net worth.
How do I contact Barbara-Jean A. Bormann-Kennedy?
Has Barbara-Jean A. Bormann-Kennedy been buying or selling shares of Xeris Biopharma?
Barbara-Jean A. Bormann-Kennedy has not been actively trading shares of Xeris Biopharma in the last ninety days. Most recently, Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a transaction totalling $97,440.00. Following the completion of the sale, the director now directly owns 126,500 shares of the company's stock, valued at $770,385. Learn More on Barbara-Jean A. Bormann-Kennedy's trading history.
Who are Xeris Biopharma's active insiders?
Xeris Biopharma's insider roster includes Barbara-Jean Bormann-Kennedy (Director), James Brady (Director), Paul Edick (Insider), Dawn Halkuff (Director), Beth Hecht (Insider), John Johnson (Director), Kevin McCulloch (President and Chief Operating Officer), Marla Persky (Director), Steven Pieper (CFO), John Shannon, Jr. (Insider), and Jeffrey Sherman (Director). Learn More on Xeris Biopharma's active insiders.
Are insiders buying or selling shares of Xeris Biopharma?
In the last year, insiders at the sold shares 26 times. They sold a total of 783,617 shares worth more than $5,702,760.60. The most recent insider tranaction occured on July, 7th when insider Steven Pieper sold 27,600 shares worth more than $235,152.00. Insiders at Xeris Biopharma own 4.4% of the company.
Learn More about insider trades at Xeris Biopharma. Information on this page was last updated on 7/7/2026.
